ArticleCell communication and signaling : CCS2026
De-2-hydroxyisobutyrylation of clusterin modulates neuropathology and memory deficits in an Alzheimer's disease mouse model.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundAlzheimer’s disease (AD) is a progressive, irreversible neurodegenerative disorder with no effective cure, posing a major clinical challenge. Lysine 2-hydroxyisobutyrylation (Khib) is a recently identified post-translational modification found across diverse species and is involved in key metabolic processes associated with the regulation of protein function. However, its role in AD remains poorly understood. This study aimed to elucidate the involvement of Khib in AD pathogenesis as well as the underlying molecular mechanisms.
methodsWe compared lysine acylation profiles between 10-month-old APP/PS1 transgenic mice and age-matched wild-type (WT) controls using western blot. Quantitative Khib proteomics was employed to identify differentially modified proteins and specific Khib sites relevant to AD. To examine functional effects, we introduced an adeno-associated virus (AAV) vector expressing clusterin (CLU) K436R—a mutation that mimics Khib deficiency—into the bilateral lateral ventricles of 8-month-old WT and APP/PS1 mice via stereotactic injection. Additionally, C8-D1A astrocytic cells were transduced with lentivirus expressing CLU K436R. Co-immunoprecipitation was used to analyze the interaction between CLU and Aβ.
resultsKhib levels were significantly elevated in the brains of 10-month-old APP/PS1 mice. Proteomic analysis identified CLU as a Khib-modified protein, with K436 as the primary modification site. CLU K436 Khib levels were significantly upregulated in APP/PS1 mice. Notably, the loss of Khib at this site in CLU K436R mutant APP/PS1 mice led to marked suppressions in the number of β-amyloid plaques, gliosis, and neuroinflammation, along with improved memory performance in vivo. In vitro, CLU K436R expression in C8-D1A astrocytes promoted glial activation and cell viability. Mechanistically, the K436R mutation influenced the CLU–Aβ interaction, thereby modulating Aβ metabolism.
conclusionsOur findings underscore a critical role for Khib in AD pathophysiology and reveal that Khib modification of CLU at K436 influences amyloid pathology, glial responses, and neuroinflammation. These results provide novel insights into the molecular mechanisms underlying AD and suggest that targeting Khib at CLU K436 may represent a promising therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.